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Quality of tuberculosis care by Indian pharmacies: Mystery clients oﬀer new
insights
A B S T R A C T
For many patients in India, pharmacies are their ﬁrst point of contact, where most drugs, including antibiotics,
can be purchased over-the-counter (OTC). Recent standardised (simulated) patient studies, covering four Indian
cities, provide new insights on how Indian pharmacies manage patients with suspected or known tuberculosis.
Correct management of the simulated patients ranged from 13% to 62%, increasing with the certainty of the TB
diagnosis. Antibiotics were frequently dispensed OTC to patients, with 16% to 37% receiving such drugs across
the cases. On a positive note, these studies showed that no pharmacy dispensed ﬁrst-line anti-TB drugs.
Engagement of pharmacies is important to not only improve TB detection and care, but also limit the abuse of
antibiotics.
Tuberculosis (TB) is the world's top infectious disease killer, accounting for an estimated 1.8 million deaths in 2015 [1]. Over a quarter of those
deaths were in India, which carries the largest burden of the disease, with worryingly high rates of MDR-TB. Early symptoms of pulmonary TB are
common, vague and persistent, leading infected individuals to seek care from a variety of local primary care providers [2]. A study of patient
pathways to care in 13 countries showed that nearly 60% of TB patients begin their care seeking in the private or informal sectors, including
pharmacies [3].
Pharmacies are highly accessible in India due to their vast numbers (around 800,000 nationally) [4], long opening hours and absence of user fees
[5]. For many patients, pharmacies may be their ﬁrst point of contact, where most drugs, including antibiotics, can be purchased over-the-counter
(OTC).
What exactly do pharmacists do when they encounter patients with suspected TB, or conﬁrmed TB? We now have reliable, consistent data from
two standardised (simulated) patient studies, across 4 Indian cities, on how Indian pharmacies manage such patients [6,7]. Standardised patients
(SPs), also called mystery clients, are widely considered to be the gold standard when it comes to measurement of actual practice [8], and SPs have
been eﬀectively used to assess quality of TB care in India, Kenya and China [9–11].
Together, the two SP studies of pharmacies in India presented three diﬀerent presentations of TB to multiple pharmacies (Table 1). Management
of the patients was benchmarked against guidelines for pharmacists from the Government of India and the Indian Pharmaceutical Association [12].
Referral to a healthcare provider without selling antibiotics or steroids was deemed ‘correct’ management (Table 1). Correct management that is
evidence-based is a core element of quality of care. There are, of course, other elements such as user experience and patient outcomes. But these were
not captured in the SP studies.
Fig. 1 shows that correct management of the SPs ranged from 13% to 62%, increasing with the certainty of the TB diagnosis. Those presenting
with non-speciﬁc symptoms of cough and fever, consistent with many diﬀerential diagnoses, were correctly managed only in 13% of the SP in-
teractions. However, the suggestion of TB, due to close contact with a relative with TB, increased this ﬁgure to 45%. Further still, a conﬁrmed
positive sputum test ensured that almost two-thirds of SPs were managed correctly.
Antibiotics were frequently dispensed OTC to patients, with 16%–37% receiving such drugs across the cases. However, three positive ﬁndings
emerged. First, antibiotic use more than halved when SPs explained they had been in contact with an infected individual or had a conﬁrmed
diagnosis, compared to those only presenting symptoms suggestive of TB. Second, the use of restricted Schedule H1 medicines was low in all cities.
Third, out of 1533 SP encounters across 4 cities, not a single pharmacy dispensed ﬁrst-line anti-TB medications without a prescription.
Successful TB control eﬀorts hinge on early diagnosis and appropriate treatment. The results of these recent SP studies are consistent across 4
cities, and show that urban pharmacists do a poor job of asking patients with TB symptoms relevant questions, and referring them for TB testing.
These practices likely delay TB diagnosis. However, a pure proﬁt motive whereby pharmacists want to sell drugs to patients at all costs is also a poor
explanation of observed behavior. Management varied with the certainty of the diagnosis and pharmacists were willing to forego sales in favor of
referring patients with a stronger suggestion of TB. Therefore, training pharmacy staﬀ to recognise the symptoms of TB could improve on the current
situation.
In terms of treatment, these studies demonstrate that pharmacists do not give OTC ﬁrst-line anti-TB drugs and are likely not a major driver of
drug resistant TB in the country. The limited use of H1 medicines (a restricted category of medicines, mainly comprising third and fourth generation
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cephalosporins, carbapenems, newer ﬂuoroquinolones and ﬁrst- and second-line anti-tuberculosis drugs) also suggests that the introduction of this
regulation has had an eﬀect.
Historically, community pharmacists have not been engaged in national policy discussions around TB control. However, recent years have seen
some progress in this area culminating in the memorandum of understanding between the Central TB Division and the Indian Pharmaceutical
Association, the All India Organisation of Chemists and Druggists, the Pharmacy Council of India and the SEARPharm forum to ``engage pharmacists
in RNTCP for TB Care and Control in India''. Over the past decade, there have been projects focused on engaging pharmacists in India [13]. But such
public-private mix (PPM) partnerships are yet to reach scale [14]. In the most recent draft of the National Strategic Plan for Tuberculosis Elimination
2017–2025, there are no budgets for engaging retail pharmacists, but mapping of pharmacies and their engagement is surveillance and social
mobilization is envisioned [15].
It is widely believed that knowledge may not be suﬃcient to ensure good pharmacy practice as public health goals may not necessarily align with
the ﬁnancial interests of private sector pharmacists [16,17]. Our ﬁndings suggest that this view needs to be nuanced: pharmacists do deviate from
accepted norms when diagnosis is unknown or uncertain. But their behavior improves markedly when diagnoses are more apparent. And their
deviations are tightly bound by implicit norms that restrict the use of anti-TB medicines and Schedule H1 antibiotics.
In conclusion, we need to think beyond traditional models that expect pharmacists to be able to recognize who may have TB and passively refer
TB patients to the public sector [18]. Pharmacists can be engaged for a variety of TB services across the cascade of care, and private pharmacies have
been actively engaged in novel PPM models in India that have dramatically increased private sector TB case notiﬁcations in the country and
improved quality of TB care in the private sector [19]. In addition, a supportive and eﬀective regulatory environment may be as important to help
curb the OTC sale of unnecessary antibiotics, and decrease diagnostic delays for millions of TB patients.
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Table 1
Speciﬁc case presentations of tuberculosis by standardised patients in Satyanarayana et al. [7] and Miller and Goodman [6].
Satyanarayana et al 2016 (Lancet case 1) Miller and Goodman 2017 (BMJGH
case)
Satyanarayana et al 2016 (Lancet case 2)
Case presentation (opening
statement by the
simulated patient)
`I have cough and fever that is not getting better.
Please give me some medicine'
`I have had cough and some fever for
3–4 weeks. We have had a relative
staying with us who has TB. Can you
suggest something?'
`I am having cough for nearly a month now and also
have fever.' While showing a positive sputum report
to the chemist, the patient continues, ‘I went to the
government dispensary and they asked me to get
my sputum tested. I have this report. Can you please
give me some medicine?’
Deﬁnition of ‘correct’
management
Verbal or written referral to a DOTS centre or a
health-care provider without dispensing any
antibiotics (including anti-tuberculosis drugs and
ﬂuoroquinolones) or steroids
Referral to TB clinic or other
healthcare provider for sputum
examination. No sale of antibiotics
(including anti-TB medication) or
steroids
Verbal or written referral to a DOTS centre or a
health-care provider without dispensing any
antibiotics (including anti-tuberculosis drugs and
ﬂuoroquinolones) or steroids
Fig. 1. Management of 3 diﬀerent case presentations of tuberculosis by
pharmacies in urban India. For deﬁnition of ‘correct management’ see Table 1.
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